Breaking News Instant updates and real-time market news.

TUFN

Tufin

$12.54 /

-0.06 (-0.48%)

08:58
05/12/22
05/12
08:58
05/12/22
08:58

Tufin reports Q1 EPS (28c), consensus (24c)

Reports Q1 revenue $26.1M, consensus $28.24M. "I'm pleased to report another strong quarter for Tufin, with product revenue growth of 61% compared to the prior year driven by increasing demand for network cyber security solutions," said Ruvi Kitov, Tufin's CEO and Co-Founder. "We continued to make significant progress in our transition to subscription in the quarter, with subscriptions representing 77% of new license bookings thus far in 2022, which positions us well ahead of our long-term goals. As we announced last month, Tufin entered into a definitive agreement to be acquired by Turn/River, a private equity firm that specializes in helping subscription-based software businesses accelerate their strategy by expanding into new markets and reaching new customer segments. With their partnership, I am confident we will be able to execute on our long-term initiatives faster and more efficiently as a privately held company."

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
Protalix to hold a KOL webcast » 23:42
12/04/22
12/04
23:42
12/04/22
23:42
PLX

Protalix

$1.14 /

+0.015 (+1.34%)

Management holds a Key…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PLX Protalix
$1.14 /

+0.015 (+1.34%)

Conference/Events
Corteva to host conference call » 23:36
12/04/22
12/04
23:36
12/04/22
23:36
CTVA

Corteva

$67.28 /

+1.045 (+1.58%)

Conference call to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CTVA Corteva
$67.28 /

+1.045 (+1.58%)

CTVA Corteva
$67.28 /

+1.045 (+1.58%)

11/17/22 Barclays
Corteva price target raised to $75 from $71 at Barclays
11/15/22 UBS
Corteva downgraded to Neutral from Buy at UBS
11/15/22 Loop Capital
Corteva downgraded to Hold from Buy at Loop Capital
11/15/22 Loop Capital
Loop Capital upgrades FMC Corporation to Buy on strong execution
CTVA Corteva
$67.28 /

+1.045 (+1.58%)

CTVA Corteva
$67.28 /

+1.045 (+1.58%)

CTVA Corteva
$67.28 /

+1.045 (+1.58%)

Conference/Events
Amgen to host conference call » 23:32
12/04/22
12/04
23:32
12/04/22
23:32
AMGN

Amgen

$285.44 /

-0.515 (-0.18%)

EVP of R&D Reese…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$285.44 /

-0.515 (-0.18%)

AMGN Amgen
$285.44 /

-0.515 (-0.18%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/17/22 Credit Suisse
Amgen initiated with an Underperform at Credit Suisse
11/08/22 Oppenheimer
Amgen price target raised to $300 from $290 at Oppenheimer
AMGN Amgen
$285.44 /

-0.515 (-0.18%)

AMGN Amgen
$285.44 /

-0.515 (-0.18%)

AMGN Amgen
$285.44 /

-0.515 (-0.18%)

AMGN Amgen
$285.44 /

-0.515 (-0.18%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:02
12/04/22
12/04
20:02
12/04/22
20:02
AAPL

Apple

$147.82 /

-0.58 (-0.39%)

, HNHPF

Hon Hai Precision

$6.81 /

+0.16 (+2.41%)

, JNJ

Johnson & Johnson

$178.84 /

+0.085 (+0.05%)

, HZNP

Horizon Therapeutics

$104.82 /

+3.94 (+3.91%)

, ABBV

AbbVie

$163.65 /

+2.03 (+1.26%)

, DIS

Disney

$99.42 /

+0.75 (+0.76%)

, BOOT

Boot Barn

$66.14 /

-0.55 (-0.82%)

, CDAY

Ceridian

$69.73 /

-1.49 (-2.09%)

, HUBS

HubSpot

$304.07 /

-2.15 (-0.70%)

, SITE

SiteOne Landscape

$126.16 /

-1.69 (-1.32%)

, STZHF

Stelco Holdings

$34.15 /

+0.61 (+1.82%)

, TPR

Tapestry

$38.82 /

+0.31 (+0.80%)

, MGY

Magnolia Oil & Gas

$25.79 /

+0.16 (+0.62%)

, SAIA

Saia

$237.86 /

-0.02 (-0.01%)

, GMVHF

Entain

$16.66 /

-0.468 (-2.73%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. In recent weeks, Apple (AAPL) has accelerated plans to shift some of its production outside China, long the dominant country in the supply chain that built the world's most valuable company, The Wall Street Journal's Yang Jie and Aaron Tilley report, citing people familiar with the matter. It is telling suppliers to plan more actively for assembling Apple products elsewhere in Asia, particularly India and Vietnam, sources say, and looking to reduce dependence on Taiwanese assemblers led by Foxconn (HNHPF). 2. Johnson & Johnson (JNJ) said it doesn't intend to make an offer for Horizon Therapeutics (HZNP), days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company, Bloomberg's Susanne Barton reports. Janssen Global Services, J&J's pharmaceutical division, didn't provide a reason why it isn't planning on proceeding with an offer, the author notes. 3. AbbVie's (ABBV) blockbuster drug Humira faces patent expirations, but there's a lot more to it than the immunosuppressive, Teresa Rivas writes in this week's edition of Barron's. The company has profitable products that have begun to fill the gap left by Humira's decline. Investors who preferred to wait out the transition from Humira may have erred-AbbVie stock is up by more than 19%, to a recent $162, so far in 2022. Moreover, the stock looks cheap and has a handsome dividend yield. It's worth owning-now, the author argues. 4. Marvel and Disney's (DIS) "Black Panther: Wakanda Forever" won this weekend's domestic box office with an estimated $17.6M from 3,855 locations for a domestic tally of $394M. Overseas, the movie earned another $20.2M for a foreign cume of $339M and $733M globally. 5. Boot Barn (BOOT), Ceridian HCM Holding (CDAY), HubSpot (HUBS), Magnolia Oil & Gas (MGY), Saia (SAIA), SiteOne Landscape Supply (SITE), Stelco Holdings (STZHF), Tapestry (TPR), and Entain (GMVHF) saw a positive mention in this week's edition of Barron's.

ShowHide Related Items >><<
TPR Tapestry
$38.82 /

+0.31 (+0.80%)

STZHF Stelco Holdings
$34.15 /

+0.61 (+1.82%)

SITE SiteOne Landscape
$126.16 /

-1.69 (-1.32%)

SAIA Saia
$237.86 /

-0.02 (-0.01%)

MGY Magnolia Oil & Gas
$25.79 /

+0.16 (+0.62%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

HUBS HubSpot
$304.07 /

-2.15 (-0.70%)

HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CDAY Ceridian
$69.73 /

-1.49 (-2.09%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

12/02/22 Morgan Stanley
Morgan Stanley sees December quarter App Store forecast as 'conservative'
12/01/22 Piper Sandler
Apple estimates lowered on shutdowns in Zhengzhou at Piper Sandler
11/30/22 Wedbush
China lockdown ends in iPhone city, heavy lifting ahead for Apple, says Wedbush
11/30/22 Baird
Apple estimates lowered due to ongoing assembly challenges, says Baird
HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

12/01/22 Goldman Sachs
Hon Hai Precision upgraded to Buy from Neutral at Goldman Sachs
03/14/22 BofA
Apple exposure to Shenzhen and Suzhou 'manageable,' says BofA
JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

11/30/22 Cowen
Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
11/01/22 H.C. Wainwright
Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

11/17/22 Credit Suisse
AbbVie initiated with an Outperform at Credit Suisse
11/08/22 Societe Generale
AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds
11/08/22 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
10/28/22 Piper Sandler
Piper keeps Overweight rating on AbbVie despite 'rough' Q3 report
DIS Disney
$99.42 /

+0.75 (+0.76%)

11/30/22 Atlantic Equities
Atlantic Equities sees 'no easy fix' for Iger at Disney
11/22/22 Tigress Financial
Disney price target lowered to $177 from $229 at Tigress Financial
11/21/22 JPMorgan
JPMorgan 'reluctant to recommend chasing' Disney shares on rally
11/21/22 Citi
Iger returning 'unalloyed positive' for Disney shares, says Citi
BOOT Boot Barn
$66.14 /

-0.55 (-0.82%)

10/27/22 Baird
Boot Barn price target lowered to $75 from $80 at Baird
10/27/22 Citi
Boot Barn price target lowered to $93 from $99 at Citi
10/18/22 Citi
Boot Barn price target lowered to $99 from $110 at Citi
08/12/22 Baird
Boot Barn removed as bullish Fresh Pick at Baird
CDAY Ceridian
$69.73 /

-1.49 (-2.09%)

11/14/22 Cowen
Ceridian price target raised to $77 from $70 at Cowen
11/03/22 Cowen
Ceridian price target raised to $70 from $67 at Cowen
10/31/22 Barclays
Ceridian upgraded to Equal Weight from Underweight at Barclays
10/21/22 Citi
Ceridian price target lowered to $68 from $73 at Citi
HUBS HubSpot
$304.07 /

-2.15 (-0.70%)

11/28/22 Needham
Needham adds HubSpot to Conviction List, removes Zuora
11/21/22 Credit Suisse
HubSpot initiated with an Outperform at Credit Suisse
11/04/22 Truist
HubSpot price target lowered to $400 from $500 at Truist
11/03/22 Cowen
HubSpot price target lowered to $380 from $390 at Cowen
SITE SiteOne Landscape
$126.16 /

-1.69 (-1.32%)

11/03/22 Baird
SiteOne Landscape price target raised to $160 from $150 at Baird
10/31/22 Stifel
SiteOne Landscape price target lowered to $110 from $120 at Stifel
10/20/22 Deutsche Bank
SiteOne Landscape price target lowered to $135 from $189 at Deutsche Bank
10/19/22 Baird
SiteOne Landscape upgraded to Outperform at Baird following pullback
STZHF Stelco Holdings
$34.15 /

+0.61 (+1.82%)

11/17/22 BMO Capital
Stelco Holdings price target raised to C$56 from C$49 at BMO Capital
11/17/22 RBC Capital
Stelco Holdings price target raised to C$44 from C$42 at RBC Capital
11/17/22 Stifel
Stelco Holdings price target raised to C$36 from C$32.50 at Stifel
11/17/22 Scotiabank
Stelco Holdings price target raised to C$45.50 from C$41.50 at Scotiabank
TPR Tapestry
$38.82 /

+0.31 (+0.80%)

11/29/22 JPMorgan
Tapestry price target raised to $47 from $46 at JPMorgan
11/14/22 Citi
Tapestry price target lowered to $40 from $42 at Citi
11/11/22 Morgan Stanley
Tapestry price target lowered to $35 from $39 at Morgan Stanley
11/04/22 Citi
Tapestry price target lowered to $42 from $46 at Citi
MGY Magnolia Oil & Gas
$25.79 /

+0.16 (+0.62%)

11/17/22 Piper Sandler
Magnolia Oil & Gas price target raised to $36 from $32 at Piper Sandler
10/18/22 Piper Sandler
Magnolia Oil & Gas price target lowered to $32 from $33 at Piper Sandler
09/19/22 KeyBanc
Magnolia Oil & Gas initiated with an Overweight at KeyBanc
07/20/22 MKM Partners
Magnolia Oil & Gas assumed with a Buy at MKM Partners
SAIA Saia
$237.86 /

-0.02 (-0.01%)

12/01/22 BofA
Saia cut to Underperform at BofA after Q4 shipment update
12/01/22 BofA
Saia downgraded to Underperform from Neutral at BofA
11/28/22 Deutsche Bank
Saia price target raised to $296 from $281 at Deutsche Bank
11/17/22 Wolfe Research
Wolfe reshuffles ratings in freight with five downgrades and one upgrade
GMVHF Entain
$16.66 /

-0.468 (-2.73%)

11/30/22 JPMorgan
Entain price target raised to 2,270 GBp from 2,050 GBp at JPMorgan
10/19/22 Barclays
Entain price target lowered to 1,450 GBp from 1,950 GBp at Barclays
10/13/22 Jefferies
Entain price target lowered to 1,900 GBp from 2,025 GBp at Jefferies
10/12/22 Redburn
Redburn launches coverage in online betting, calls Flutter top pick
TPR Tapestry
$38.82 /

+0.31 (+0.80%)

SITE SiteOne Landscape
$126.16 /

-1.69 (-1.32%)

SAIA Saia
$237.86 /

-0.02 (-0.01%)

MGY Magnolia Oil & Gas
$25.79 /

+0.16 (+0.62%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

HUBS HubSpot
$304.07 /

-2.15 (-0.70%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CDAY Ceridian
$69.73 /

-1.49 (-2.09%)

BOOT Boot Barn
$66.14 /

-0.55 (-0.82%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

  • 04
    Nov
  • 02
    Jun
  • 10
    Mar
STZHF Stelco Holdings
$34.15 /

+0.61 (+1.82%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

BOOT Boot Barn
$66.14 /

-0.55 (-0.82%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

TPR Tapestry
$38.82 /

+0.31 (+0.80%)

SITE SiteOne Landscape
$126.16 /

-1.69 (-1.32%)

SAIA Saia
$237.86 /

-0.02 (-0.01%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

HUBS HubSpot
$304.07 /

-2.15 (-0.70%)

HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CDAY Ceridian
$69.73 /

-1.49 (-2.09%)

BOOT Boot Barn
$66.14 /

-0.55 (-0.82%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

TPR Tapestry
$38.82 /

+0.31 (+0.80%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CDAY Ceridian
$69.73 /

-1.49 (-2.09%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

Periodicals
Credit Suisse's investment bank spinoff attracts Saudi Crown Prince, WSJ says » 19:47
12/04/22
12/04
19:47
12/04/22
19:47
BCS

Barclays

$7.83 /

-0.065 (-0.82%)

, CS

Credit Suisse

$3.38 /

+0.29 (+9.39%)

Saudi Arabia's crown…

Saudi Arabia's crown prince and a U.S. private-equity firm run by Barclays's (BCS) former chief executive are among investors preparing to invest $1 billion or more into Credit Suisse's (CS) new investment bank, The Wall Street Journal's Justin Baer, Margot Patrick, and Summer Said report, citing people familiar with the matter. Crown Prince Mohammed bin Salman is considering an investment of around $500 million to back the new unit, CS First Boston, and its CEO-designate, Michael Klein, some of the people said. Additional financial backing could come from U.S. investors including veteran banker Bob Diamond's Atlas Merchant Capital, people familiar with that potential investment said. Reference Link

ShowHide Related Items >><<
CS Credit Suisse
$3.38 /

+0.29 (+9.39%)

BCS Barclays
$7.83 /

-0.065 (-0.82%)

BCS Barclays
$7.83 /

-0.065 (-0.82%)

10/27/22 RBC Capital
Barclays price target raised to 180 GBp from 170 GBp at RBC Capital
10/27/22 Credit Suisse
Barclays price target raised to 250 GBp from 240 GBp at Credit Suisse
10/11/22 JPMorgan
Barclays price target lowered to 180 GBp from 200 GBp at JPMorgan
09/06/22 JPMorgan
Barclays price target raised to 200 GBp from 190 GBp at JPMorgan
CS Credit Suisse
$3.38 /

+0.29 (+9.39%)

12/01/22 JPMorgan
Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan
11/07/22 AlphaValue/Baader
Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
10/28/22 JPMorgan
Credit Suisse price target lowered to CHF 5.50 from CHF 6 at JPMorgan
10/06/22 JPMorgan
Credit Suisse upgraded to Neutral from Underweight at JPMorgan
CS Credit Suisse
$3.38 /

+0.29 (+9.39%)

BCS Barclays
$7.83 /

-0.065 (-0.82%)

CS Credit Suisse
$3.38 /

+0.29 (+9.39%)

BCS Barclays
$7.83 /

-0.065 (-0.82%)

CS Credit Suisse
$3.38 /

+0.29 (+9.39%)

BCS Barclays
$7.83 /

-0.065 (-0.82%)

CS Credit Suisse
$3.38 /

+0.29 (+9.39%)

BCS Barclays
$7.83 /

-0.065 (-0.82%)

Conference/Events
Replimune Group to host virtual investor day » 18:08
12/04/22
12/04
18:08
12/04/22
18:08
REPL

Replimune Group

$20.30 /

+0.39 (+1.96%)

Virtual Investor Event to…

Virtual Investor Event to be held on December 7 at 8 am. Webcast Link

ShowHide Related Items >><<
REPL Replimune Group
$20.30 /

+0.39 (+1.96%)

REPL Replimune Group
$20.30 /

+0.39 (+1.96%)

10/14/22 BMO Capital
Replimune Group price target raised to $40 from $30 at BMO Capital
08/16/22 Piper Sandler
Replimune Group price target lowered to $43 from $44 at Piper Sandler
05/24/22 Wedbush
Replimune Group price target lowered to $52 from $59 at Wedbush
05/19/22 Piper Sandler
Replimune Group price target lowered to $44 from $52 at Piper Sandler
REPL Replimune Group
$20.30 /

+0.39 (+1.96%)

Hot Stocks
TherapeuticsMD enters agreements to license products to Mayne Pharma » 18:04
12/04/22
12/04
18:04
12/04/22
18:04
TXMD

TherapeuticsMD

$4.40 /

+0.03 (+0.69%)

TherapeuticsMD announced…

TherapeuticsMD announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma for commercialization in the United States. In addition, TherapeuticsMD has agreed to sell certain assets to Mayne Pharma to allow Mayne Pharma to commercialize the products. At closing of the transaction, TherapeuticsMD will receive an upfront cash payment of $140.0 million for the license grant and sale of certain assets, plus an additional approximately $13.1 million, subject to customary adjustments, for acquired net working capital. In addition, TherapeuticsMD will receive a 20-year royalty stream tied to Mayne Pharma's net sales of the products. The upfront payment to be made by Mayne Pharma, along with cash on hand, will allow TherapeuticsMD to repay its outstanding indebtedness with Sixth Street Partners and to redeem its outstanding preferred equity, with TherapeuticsMD continuing as a pharmaceutical royalty company with the potential to create value for stakeholders over time from the resulting net cash flows. Under the terms of the transaction, TherapeuticsMD will grant Mayne Pharma an exclusive license to commercialize the company's Imvexxy, Bijuva, and its prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and will assign to Mayne Pharma the company's exclusive license to commercialize Annovera in the United States. In addition, TherapeuticsMD will sell to Mayne Pharma certain assets to allow Mayne Pharma to commercialize the Products, including inventory. Upon completion of the transaction, which is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Act of 1976, Mayne Pharma will be responsible for development, regulatory filings, manufacturing, and commercialization of the Products. In connection with entering into the transaction, the lenders and administrative agent under the company's Financing Agreement with Sixth Street Partners have agreed to extend the maturity date of the Financing Agreement to December 31, 2022, allowing the company to complete the transaction with Mayne Pharma on or before that date. The maturity date of the Financing Agreement may be further extended to January 31, 2023, upon payment of an amendment fee, in the event the definitive agreements in connection with the transaction remain in effect and the waiting period under the HSR Act has not expired or terminated. The company will retain its existing licensing agreements with Knight Therapeutics and Theramex HQ UK Limited. The transaction is not subject to any financing conditions and is expected to close at the end of 2022, pending satisfaction of customary closing conditions.

ShowHide Related Items >><<
TXMD TherapeuticsMD
$4.40 /

+0.03 (+0.69%)

TXMD TherapeuticsMD
$4.40 /

+0.03 (+0.69%)

07/15/22 H.C. Wainwright
H.C. Wainwright suspends rating on TherapeuticsMD with merger terminated
06/07/22 H.C. Wainwright
TherapeuticsMD downgraded to Neutral from Buy at H.C. Wainwright
05/06/22 Cantor Fitzgerald
TherapeuticsMD downgraded to Neutral from Overweight at Cantor Fitzgerald
05/06/22 Cantor Fitzgerald
TherapeuticsMD downgraded to Neutral from Overweight at Cantor Fitzgerald
TXMD TherapeuticsMD
$4.40 /

+0.03 (+0.69%)

TXMD TherapeuticsMD
$4.40 /

+0.03 (+0.69%)

TXMD TherapeuticsMD
$4.40 /

+0.03 (+0.69%)

Conference/Events
IFF to host virtual investor day » 18:02
12/04/22
12/04
18:02
12/04/22
18:02
IFF

IFF

$107.97 /

+1.28 (+1.20%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 7 at 1 pm. Webcast Link

ShowHide Related Items >><<
IFF IFF
$107.97 /

+1.28 (+1.20%)

IFF IFF
$107.97 /

+1.28 (+1.20%)

11/11/22 Deutsche Bank
IFF price target lowered to $110 from $115 at Deutsche Bank
11/09/22 Credit Suisse
IFF price target lowered to $125 from $130 at Credit Suisse
11/09/22 Mizuho
IFF price target lowered to $116 from $145 at Mizuho
11/09/22 Baird
IFF price target lowered to $120 from $140 at Baird
IFF IFF
$107.97 /

+1.28 (+1.20%)

IFF IFF
$107.97 /

+1.28 (+1.20%)

Conference/Events
Acadia Healthcare to host investor day » 17:56
12/04/22
12/04
17:56
12/04/22
17:56
ACHC

Acadia Healthcare

$87.50 /

-0.07 (-0.08%)

Investor day to be held…

Investor day to be held on December 7 at 9 am. Webcast Link

ShowHide Related Items >><<
ACHC Acadia Healthcare
$87.50 /

-0.07 (-0.08%)

ACHC Acadia Healthcare
$87.50 /

-0.07 (-0.08%)

11/02/22 Mizuho
Acadia Healthcare price target raised to $80 from $78 at Mizuho
08/26/22 SVB Securities
Acadia Healthcare price target raised to $103 from $95 at SVB Securities
08/01/22 Deutsche Bank
Acadia Healthcare price target raised to $82 from $70 at Deutsche Bank
08/01/22 RBC Capital
Acadia Healthcare price target raised to $94 from $84 at RBC Capital
ACHC Acadia Healthcare
$87.50 /

-0.07 (-0.08%)

ACHC Acadia Healthcare
$87.50 /

-0.07 (-0.08%)

Conference/Events
Fortune Brands to host investor day » 17:37
12/04/22
12/04
17:37
12/04/22
17:37
FBHS

Fortune Brands

$63.57 /

-1.98 (-3.02%)

Investor Day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FBHS Fortune Brands
$63.57 /

-1.98 (-3.02%)

FBHS Fortune Brands
$63.57 /

-1.98 (-3.02%)

10/31/22 BMO Capital
Fortune Brands price target lowered to $85 from $90 at BMO Capital
10/27/22 Baird
Fortune Brands price target raised to $70 from $65 at Baird
10/20/22 Deutsche Bank
Fortune Brands price target lowered to $90 from $100 at Deutsche Bank
10/18/22 BofA
Fortune Brands price target lowered to $60 from $70 at BofA
FBHS Fortune Brands
$63.57 /

-1.98 (-3.02%)

FBHS Fortune Brands
$63.57 /

-1.98 (-3.02%)

Conference/Events
Eagle Pharmaceuticals to host investor day » 17:32
12/04/22
12/04
17:32
12/04/22
17:32
EGRX

Eagle Pharmaceuticals

$35.85 /

+0.52 (+1.47%)

Investor Day to be held…

Investor Day to be held in New York on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
EGRX Eagle Pharmaceuticals
$35.85 /

+0.52 (+1.47%)

EGRX Eagle Pharmaceuticals
$35.85 /

+0.52 (+1.47%)

12/16/21 Barclays
Endo price target lowered to $5 from $7 at Barclays
12/15/21 Cantor Fitzgerald
Vasopressin approval 'a key win' for Eagle Pharmaceuticals, says Cantor
EGRX Eagle Pharmaceuticals
$35.85 /

+0.52 (+1.47%)

On The Fly
Box Office Battle: ‘Black Panther 2’ wins weekend with another $17.6M » 17:30
12/04/22
12/04
17:30
12/04/22
17:30
WBD

Warner Bros. Discovery

$11.56 /

-0.065 (-0.56%)

, CMCSA

Comcast

$35.85 /

-0.44 (-1.21%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SONY

Sony

$82.78 /

-1.11 (-1.32%)

, LGF.A

Lionsgate

$7.78 /

+0.54 (+7.46%)

, LGF.B

Lionsgate

$7.24 /

+0.53 (+7.90%)

, DIS

Disney

$99.42 /

+0.75 (+0.76%)

, PARA

Paramount

$20.41 /

+0.235 (+1.16%)

"Box Office Battle" is…

ShowHide Related Items >><<
WBD Warner Bros. Discovery
$11.56 /

-0.065 (-0.56%)

SONY Sony
$82.78 /

-1.11 (-1.32%)

PARA Paramount
$20.41 /

+0.235 (+1.16%)

LGF.B Lionsgate
$7.24 /

+0.53 (+7.90%)

LGF.A Lionsgate
$7.78 /

+0.54 (+7.46%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$35.85 /

-0.44 (-1.21%)

WBD Warner Bros. Discovery
$11.56 /

-0.065 (-0.56%)

11/14/22 Spin-Off Research
Warner Bros. Discovery downgraded to Hold from Buy at Spin-Off Research
11/10/22 Citi
Warner Bros. Discovery price target lowered to $18 from $21 at Citi
11/08/22 Deutsche Bank
Warner Bros. Discovery price target lowered to $35 from $48 at Deutsche Bank
11/07/22 RBC Capital
Warner Bros. Discovery price target lowered to $27 from $44 at RBC Capital
CMCSA Comcast
$35.85 /

-0.44 (-1.21%)

11/21/22 JPMorgan
JPMorgan 'reluctant to recommend chasing' Disney shares on rally
10/31/22 Scotiabank
Cogeco Communications downgraded to Sector Perform from Outperform at Scotiabank
10/28/22 Cowen
Comcast price target lowered to $49 from $51 at Cowen
10/27/22 Pivotal Research
Comcast price target lowered to $42 from $47 at Pivotal Research
CMCSK Comcast
$58.00 /

+ (+0.00%)

09/27/22 Credit Suisse
Charter price target lowered to $551 from $676 at Credit Suisse
09/27/22 Credit Suisse
Comcast price target lowered to $51 from $57 at Credit Suisse
07/20/22 KeyBanc
Disney price target lowered to $131 from $151 at KeyBanc
05/23/22 Raymond James
Electronic Arts moves 'somewhat unexpected,' says Raymond James
SONY Sony
$82.78 /

-1.11 (-1.32%)

11/02/22 Cowen
Sony price target lowered to $102 from $144 at Cowen
10/13/22 Oppenheimer
Oppenheimer sees more difficulty for Microsoft/Activision to win CMA approval
09/07/22 Goldman Sachs
Sony resumed with a Neutral at Goldman Sachs
07/08/22 Macquarie
Sony upgraded to Outperform, added to 'Marquee Buy' list at Macquarie
LGF.A Lionsgate
$7.78 /

+0.54 (+7.46%)

09/29/22 Benchmark
Lionsgate price target lowered to $18 from $20 at Benchmark
09/07/22 Wolfe Research
Lionsgate downgraded to Peer Perform from Outperform at Wolfe Research
06/03/22 Deutsche Bank
Lionsgate price target lowered to $13 from $16 at Deutsche Bank
06/02/22 Wolfe Research
Lionsgate initiated with an Outperform at Wolfe Research
LGF.B Lionsgate
$7.24 /

+0.53 (+7.90%)

10/26/22 Truist
Lionsgate price target lowered to $11 from $14 at Truist
08/02/22 Truist
Lionsgate price target lowered to $14 from $15 at Truist
07/18/22 Morgan Stanley
Lionsgate price target lowered to $9.50 from $11 at Morgan Stanley
DIS Disney
$99.42 /

+0.75 (+0.76%)

11/30/22 Atlantic Equities
Atlantic Equities sees 'no easy fix' for Iger at Disney
11/22/22 Tigress Financial
Disney price target lowered to $177 from $229 at Tigress Financial
11/21/22 Citi
Iger returning 'unalloyed positive' for Disney shares, says Citi
PARA Paramount
$20.41 /

+0.235 (+1.16%)

11/04/22 Deutsche Bank
Paramount price target lowered to $28 from $32 at Deutsche Bank
11/03/22 Morgan Stanley
Paramount price target lowered to $15 from $20 at Morgan Stanley
11/03/22 Benchmark
Paramount price target lowered to $31 from $47 at Benchmark
10/31/22 Wells Fargo
Paramount downgraded to Underweight from Equal Weight at Wells Fargo
WBD Warner Bros. Discovery
$11.56 /

-0.065 (-0.56%)

SONY Sony
$82.78 /

-1.11 (-1.32%)

PARA Paramount
$20.41 /

+0.235 (+1.16%)

LGF.A Lionsgate
$7.78 /

+0.54 (+7.46%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CMCSA Comcast
$35.85 /

-0.44 (-1.21%)

WBD Warner Bros. Discovery
$11.56 /

-0.065 (-0.56%)

SONY Sony
$82.78 /

-1.11 (-1.32%)

PARA Paramount
$20.41 /

+0.235 (+1.16%)

LGF.A Lionsgate
$7.78 /

+0.54 (+7.46%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$35.85 /

-0.44 (-1.21%)

WBD Warner Bros. Discovery
$11.56 /

-0.065 (-0.56%)

SONY Sony
$82.78 /

-1.11 (-1.32%)

PARA Paramount
$20.41 /

+0.235 (+1.16%)

LGF.A Lionsgate
$7.78 /

+0.54 (+7.46%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CMCSA Comcast
$35.85 /

-0.44 (-1.21%)

WBD Warner Bros. Discovery
$11.56 /

-0.065 (-0.56%)

SONY Sony
$82.78 /

-1.11 (-1.32%)

PARA Paramount
$20.41 /

+0.235 (+1.16%)

DIS Disney
$99.42 /

+0.75 (+0.76%)

CMCSA Comcast
$35.85 /

-0.44 (-1.21%)

Conference/Events
Patria Investments to host investor day » 17:29
12/04/22
12/04
17:29
12/04/22
17:29
PAX

Patria Investments

$13.61 /

+0.03 (+0.22%)

Investor Day to be held…

Investor Day to be held in New York on December 5 at 1 pm. Webcast Link

ShowHide Related Items >><<
PAX Patria Investments
$13.61 /

+0.03 (+0.22%)

PAX Patria Investments
$13.61 /

+0.03 (+0.22%)

09/07/22 BofA
BofA reinstates Patria Investments with a Neutral, $17 target
09/07/22 BofA
Patria Investments reinstated with a Neutral at BofA
PAX Patria Investments
$13.61 /

+0.03 (+0.22%)

Periodicals
Musk says Apple 'fully' advertising on Twitter again, Bloomberg reports » 17:17
12/04/22
12/04
17:17
12/04/22
17:17
AAPL

Apple

$147.82 /

-0.58 (-0.39%)

, TWTR

Twitter

$53.71 /

+ (+0.00%)

Elon Musk said Apple…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

12/02/22 Morgan Stanley
Morgan Stanley sees December quarter App Store forecast as 'conservative'
12/01/22 Piper Sandler
Apple estimates lowered on shutdowns in Zhengzhou at Piper Sandler
11/30/22 Wedbush
China lockdown ends in iPhone city, heavy lifting ahead for Apple, says Wedbush
11/30/22 Baird
Apple estimates lowered due to ongoing assembly challenges, says Baird
TWTR Twitter
$53.71 /

+ (+0.00%)

11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
10/31/22 Gordon Haskett
Gordon Haskett wonders if 'more going on' as Fertitta takes stake in Wynn
10/21/22 Wedbush
Twitter deal still 'brutal situation' for Tesla holders, Wedbush says
10/18/22 Gordon Haskett
Bilson sees Tesla share sale coming with Musk $8B short for Twitter
TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

TWTR Twitter
$53.71 /

+ (+0.00%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

Periodicals
Apple accelerates plans to move some production out of China, WSJ says » 17:13
12/04/22
12/04
17:13
12/04/22
17:13
AAPL

Apple

$147.82 /

-0.58 (-0.39%)

, HNHPF

Hon Hai Precision

$6.81 /

+0.16 (+2.41%)

In recent weeks, Apple…

In recent weeks, Apple (AAPL) has accelerated plans to shift some of its production outside China, long the dominant country in the supply chain that built the world's most valuable company, The Wall Street Journal's Yang Jie and Aaron Tilley report, citing people familiar with the matter. It is telling suppliers to plan more actively for assembling Apple products elsewhere in Asia, particularly India and Vietnam, sources say, and looking to reduce dependence on Taiwanese assemblers led by Foxconn (HNHPF). Reference Link

ShowHide Related Items >><<
HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

12/02/22 Morgan Stanley
Morgan Stanley sees December quarter App Store forecast as 'conservative'
12/01/22 Piper Sandler
Apple estimates lowered on shutdowns in Zhengzhou at Piper Sandler
11/30/22 Wedbush
China lockdown ends in iPhone city, heavy lifting ahead for Apple, says Wedbush
11/30/22 Baird
Apple estimates lowered due to ongoing assembly challenges, says Baird
HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

12/01/22 Goldman Sachs
Hon Hai Precision upgraded to Buy from Neutral at Goldman Sachs
03/14/22 BofA
Apple exposure to Shenzhen and Suzhou 'manageable,' says BofA
AAPL Apple
$147.82 /

-0.58 (-0.39%)

HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

HNHPF Hon Hai Precision
$6.81 /

+0.16 (+2.41%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

AAPL Apple
$147.82 /

-0.58 (-0.39%)

Periodicals
AT&T to pay $6M to SEC over private calls to analysts, Bloomberg reports » 17:09
12/04/22
12/04
17:09
12/04/22
17:09
T

AT&T

$19.01 /

-0.175 (-0.91%)

AT&T agreed to pay a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
T AT&T
$19.01 /

-0.175 (-0.91%)

T AT&T
$19.01 /

-0.175 (-0.91%)

11/14/22 Wells Fargo
Dycom price target lowered to $120 from $130 at Wells Fargo
10/24/22 Raymond James
AT&T upgraded to Strong Buy from Outperform at Raymond James
10/24/22 Barclays
AT&T price target raised to $19 from $18 at Barclays
10/24/22 Raymond James
AT&T upgraded to Strong Buy from Outperform at Raymond James
T AT&T
$19.01 /

-0.175 (-0.91%)

T AT&T
$19.01 /

-0.175 (-0.91%)

T AT&T
$19.01 /

-0.175 (-0.91%)

T AT&T
$19.01 /

-0.175 (-0.91%)

Periodicals
J&J says won't make offer for Horizon Therapeutics, Bloomberg reports » 17:07
12/04/22
12/04
17:07
12/04/22
17:07
JNJ

Johnson & Johnson

$178.84 /

+0.085 (+0.05%)

, HZNP

Horizon Therapeutics

$104.82 /

+3.94 (+3.91%)

Johnson & Johnson…

Johnson & Johnson (JNJ) said it doesn't intend to make an offer for Horizon Therapeutics (HZNP), days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company, Bloomberg's Susanne Barton reports. Janssen Global Services, J&J's pharmaceutical division, didn't provide a reason why it isn't planning on proceeding with an offer, the author notes. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

11/30/22 Cowen
Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
11/01/22 H.C. Wainwright
Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

JNJ Johnson & Johnson
$178.84 /

+0.085 (+0.05%)

HZNP Horizon Therapeutics
$104.82 /

+3.94 (+3.91%)

Periodicals
CVS testing remote system to help fill prescriptions, WSJ reports » 17:03
12/04/22
12/04
17:03
12/04/22
17:03
CVS

CVS Health

$102.56 /

+0.92 (+0.91%)

CVS Health is testing a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CVS CVS Health
$102.56 /

+0.92 (+0.91%)

CVS CVS Health
$102.56 /

+0.92 (+0.91%)

11/23/22 Morgan Stanley
CVS Health assumed with an Overweight at Morgan Stanley
11/21/22 Credit Suisse
CVS Health price target raised to $125 from $117 at Credit Suisse
11/06/22 Raymond James
CVS Health price target lowered to $115 from $120 at Raymond James
11/02/22 B. Riley
B. Riley downgrades Semler Scientific on risk from Signify buyout
CVS CVS Health
$102.56 /

+0.92 (+0.91%)

CVS CVS Health
$102.56 /

+0.92 (+0.91%)

CVS CVS Health
$102.56 /

+0.92 (+0.91%)

CVS CVS Health
$102.56 /

+0.92 (+0.91%)

Periodicals
OPEC+ keeps oil curbs despite Russia price cap, WSJ reports » 16:07
12/04/22
12/04
16:07
12/04/22
16:07
BP

BP

$35.37 /

-0.35 (-0.98%)

, COP

ConocoPhillips

$122.12 /

-0.9 (-0.73%)

, SHEL

Shell

$57.70 /

-0.365 (-0.63%)

, TTE

TotalEnergies

$60.65 /

-0.1239 (-0.20%)

, XOM

Exxon Mobil

$109.86 /

-1.02 (-0.92%)

, CVX

Chevron

$180.96 /

-1.58 (-0.87%)

, USO

United States Oil Fund

$69.84 /

-0.62 (-0.88%)

OPEC+ said Sunday it…

OPEC+ said Sunday it would keep output steady ahead of a momentous week in global energy markets, as wealthy nations impose a price cap on Moscow's petroleum exports, the European Union launches a ban on Russian oil, and Chinese leader Xi Jinping visits Saudi Arabia, The Wall Street Journal's Benoit Faucon and Summer Said report. The decision on Sunday allows the Organization of the Petroleum Exporting Countries and a group of producers led by Russia-collectively known as OPEC+-to take more time to assess the market impact of a European Union and Group of Seven price cap of $60 a barrel on Moscow's oil intended to slow down the revenue stream for the Ukraine war. It locks in a 2 million-barrels-a-day production cut decided in October, the authors note. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Shell (SHEL) and TotalEnergies (TTE).Reference Link

ShowHide Related Items >><<
XOM Exxon Mobil
$109.86 /

-1.02 (-0.92%)

USO United States Oil Fund
$69.84 /

-0.62 (-0.88%)

TTE TotalEnergies
$60.65 /

-0.1239 (-0.20%)

SHEL Shell
$57.70 /

-0.365 (-0.63%)

CVX Chevron
$180.96 /

-1.58 (-0.87%)

COP ConocoPhillips
$122.12 /

-0.9 (-0.73%)

BP BP
$35.37 /

-0.35 (-0.98%)

BP BP
$35.37 /

-0.35 (-0.98%)

12/02/22 JPMorgan
BP price target raised to 560 GBp from 530 GBp at JPMorgan
11/22/22 Citi
BP upgraded to Buy from Neutral at Citi
11/14/22 Wells Fargo
Archaea Energy downgraded to Equal Weight from Overweight at Wells Fargo
11/11/22 Piper Sandler
BP price target raised to $40 from $37 at Piper Sandler
COP ConocoPhillips
$122.12 /

-0.9 (-0.73%)

11/22/22 Citi
ConocoPhillips price target raised to $160 from $132 at Citi
11/21/22 Argus
ConocoPhillips price target raised to $150 from $125 at Argus
11/21/22 Societe Generale
ConocoPhillips downgraded to Sell on valuation at Societe Generale
11/21/22 Societe Generale
ConocoPhillips downgraded to Sell from Hold at Societe Generale
SHEL Shell
$57.70 /

-0.365 (-0.63%)

12/02/22 JPMorgan
Shell price target raised to 2,950 GBp from 2,900 GBp at JPMorgan
11/11/22 Piper Sandler
Shell price target raised to $71 from $65 at Piper Sandler
11/08/22 Morgan Stanley
Shell price target raised to 2,922 GBp from 2,860 GBp at Morgan Stanley
11/06/22 Goldman Sachs
Shell downgraded to Neutral from Buy at Goldman Sachs
TTE TotalEnergies
$60.65 /

-0.1239 (-0.20%)

12/02/22 JPMorgan
TotalEnergies price target raised to EUR 68 from EUR 66 at JPMorgan
12/02/22 JPMorgan
TotalEnergies added to Analyst Focus List at JPMorgan
11/11/22 Piper Sandler
TotalEnergies price target raised to $66 from $58 at Piper Sandler
11/08/22 Morgan Stanley
TotalEnergies price target raised to EUR 65 from EUR 58 at Morgan Stanley
XOM Exxon Mobil
$109.86 /

-1.02 (-0.92%)

11/22/22 Citi
Exxon Mobil price target raised to $110 from $98 at Citi
11/11/22 Piper Sandler
Exxon Mobil price target raised to $131 from $113 at Piper Sandler
11/01/22 Exane BNP Paribas
Exxon Mobil upgraded to Neutral from Underperform at Exane BNP Paribas
10/31/22 Truist
Exxon Mobil price target raised to $114 from $111 at Truist
CVX Chevron
$180.96 /

-1.58 (-0.87%)

11/22/22 Citi
Chevron price target raised to $180 from $155 at Citi
11/11/22 Piper Sandler
Chevron price target raised to $206 from $186 at Piper Sandler
10/31/22 Cowen
Chevron price target raised to $185 from $160 at Cowen
10/24/22 HSBC
Chevron downgraded to Hold from Buy at HSBC
USO United States Oil Fund
$69.84 /

-0.62 (-0.88%)

XOM Exxon Mobil
$109.86 /

-1.02 (-0.92%)

SHEL Shell
$57.70 /

-0.365 (-0.63%)

CVX Chevron
$180.96 /

-1.58 (-0.87%)

COP ConocoPhillips
$122.12 /

-0.9 (-0.73%)

BP BP
$35.37 /

-0.35 (-0.98%)

XOM Exxon Mobil
$109.86 /

-1.02 (-0.92%)

USO United States Oil Fund
$69.84 /

-0.62 (-0.88%)

SHEL Shell
$57.70 /

-0.365 (-0.63%)

CVX Chevron
$180.96 /

-1.58 (-0.87%)

BP BP
$35.37 /

-0.35 (-0.98%)

XOM Exxon Mobil
$109.86 /

-1.02 (-0.92%)

TTE TotalEnergies
$60.65 /

-0.1239 (-0.20%)

SHEL Shell
$57.70 /

-0.365 (-0.63%)

CVX Chevron
$180.96 /

-1.58 (-0.87%)

COP ConocoPhillips
$122.12 /

-0.9 (-0.73%)

BP BP
$35.37 /

-0.35 (-0.98%)

XOM Exxon Mobil
$109.86 /

-1.02 (-0.92%)

USO United States Oil Fund
$69.84 /

-0.62 (-0.88%)

SHEL Shell
$57.70 /

-0.365 (-0.63%)

CVX Chevron
$180.96 /

-1.58 (-0.87%)

COP ConocoPhillips
$122.12 /

-0.9 (-0.73%)

BP BP
$35.37 /

-0.35 (-0.98%)

Downgrade
Canadian Western downgraded to Market Perform from Outperform at Keefe Bruyette » 13:14
12/04/22
12/04
13:14
12/04/22
13:14
CBWBF

Canadian Western Bank

$17.99 /

-1.14 (-5.96%)

Keefe Bruyette analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CBWBF Canadian Western Bank
$17.99 /

-1.14 (-5.96%)

11/22/22 Scotiabank
Canadian Western Bank price target lowered to C$29 from C$30 at Scotiabank
11/18/22 National Bank
Canadian Western Bank price target lowered to C$34 from C$38 at National Bank
08/29/22 BMO Capital
Canadian Western Bank price target lowered to C$35 from C$39.50 at BMO Capital
08/29/22 Desjardins
Canadian Western Bank price target lowered to C$33 from C$36 at Desjardins
Recommendations
Cracker Barrel price target lowered to $86 from $94 at Citi » 10:35
12/04/22
12/04
10:35
12/04/22
10:35
CBRL

Cracker Barrel

$98.88 /

-14.58 (-12.85%)

Citi analyst Jon Tower…

Citi analyst Jon Tower lowered the firm's price target on Cracker Barrel to $86 from $94 and keeps a Sell rating on the shares post the fiscal Q1 results. The company's guidance "embeds a significant improvement" in margins by fiscal Q4, "which we believe comes with high risk," Tower tells investors in a research note. The analyst says Cracker Barrel's underlying deterioration in dining room traffic suggests the sales guidance may carry greater risk than prior, and that a "slowdown here may take an even bigger toll on retail markdowns."

ShowHide Related Items >><<
CBRL Cracker Barrel
$98.88 /

-14.58 (-12.85%)

CBRL Cracker Barrel
$98.88 /

-14.58 (-12.85%)

11/29/22 Truist
Cracker Barrel price target raised to $109 from $96 at Truist
09/28/22 Truist
Cracker Barrel price target lowered to $96 from $100 at Truist
09/28/22 Deutsche Bank
Cracker Barrel price target raised to $106 from $100 at Deutsche Bank
09/28/22 Citi
Cracker Barrel price target lowered to $90 from $98 at Citi
CBRL Cracker Barrel
$98.88 /

-14.58 (-12.85%)

CBRL Cracker Barrel
$98.88 /

-14.58 (-12.85%)

On The Fly
Short Report: Bears growl at crypto stocks amid FTX fallout » 10:34
12/03/22
12/03
10:34
12/03/22
10:34
MARA

Marathon Digital

$6.91 /

+0.69 (+11.09%)

, RIOT

Riot Blockchain

$4.97 /

+0.4 (+8.75%)

, MSTR

MicroStrategy

$206.98 /

+8.55 (+4.31%)

, SI

Silvergate Capital

$26.48 /

+1.25 (+4.95%)

, GRPN

Groupon

$8.40 /

-0.33 (-3.78%)

, RKT

Rocket Companies

$8.40 /

-0.145 (-1.70%)

, ATUS

Altice USA

$4.29 /

+0.19 (+4.64%)

, CUTR

Cutera

$51.30 /

+1.3 (+2.60%)

Welcome to this week’s…

ShowHide Related Items >><<
SI Silvergate Capital
$26.48 /

+1.25 (+4.95%)

RKT Rocket Companies
$8.40 /

-0.145 (-1.70%)

MSTR MicroStrategy
$206.98 /

+8.55 (+4.31%)

MARA Marathon Digital
$6.91 /

+0.69 (+11.09%)

GRPN Groupon
$8.40 /

-0.33 (-3.78%)

CUTR Cutera
$51.30 /

+1.3 (+2.60%)

ATUS Altice USA
$4.29 /

+0.19 (+4.64%)

MARA Marathon Digital
$6.91 /

+0.69 (+11.09%)

11/08/22 Jefferies
Marathon Digital price target lowered to $12.50 from $24 at Jefferies
10/25/22 Compass Point
Marathon Digital price target lowered to $21 from $30 at Compass Point
10/07/22 B. Riley
Marathon Digital price target lowered to $8 from $10 at B. Riley
09/23/22 BTIG
Marathon Digital cut to Neutral at BTIG on bankruptcy of its hosting provider
RIOT Riot Blockchain
$4.97 /

+0.4 (+8.75%)

11/23/22 H.C. Wainwright
Riot Blockchain assumed with a Buy at H.C. Wainwright
11/08/22 B. Riley
Riot Blockchain price target lowered to $11 from $13 at B. Riley
10/25/22 Compass Point
Riot Blockchain price target lowered to $11 from $14 at Compass Point
10/07/22 B. Riley
Riot Blockchain price target lowered to $13 from $16 at B. Riley
MSTR MicroStrategy
$206.98 /

+8.55 (+4.31%)

11/09/22 Jefferies
MicroStrategy price target lowered to $140 from $175 at Jefferies
10/31/22 Jefferies
MicroStrategy price target lowered to $175 from $180 at Jefferies
08/03/22 Canaccord
MicroStrategy price target lowered to $372 from $453 at Canaccord
07/26/22 Jefferies
MicroStrategy downgraded to Underperform from Hold at Jefferies
SI Silvergate Capital
$26.48 /

+1.25 (+4.95%)

11/29/22 Keefe Bruyette
Silvergate exposure to BlockFi 'very modest,' says Keefe Bruyette
11/25/22 Morgan Stanley
Silvergate Capital price target lowered to $24 from $37 at Morgan Stanley
11/22/22 BTIG
Silvergate Capital price target lowered to $51 from $135 at BTIG
11/21/22 Craig-Hallum
Silvergate Capital price target lowered to $36 from $100 at Craig-Hallum
GRPN Groupon
$8.40 /

-0.33 (-3.78%)

11/08/22 Barclays
Groupon price target lowered to $6 from $10 at Barclays
08/10/22 Barclays
Groupon price target lowered to $10 from $12 at Barclays
05/10/22 Wedbush
Groupon price target lowered to $15 from $22 at Wedbush
05/10/22 Barclays
Groupon price target lowered to $12 from $20 at Barclays
RKT Rocket Companies
$8.40 /

-0.145 (-1.70%)

11/16/22 Argus
Rocket Companies cut to Sell at Argus on decline in mortgage originations
11/16/22 Argus
Rocket Companies downgraded to Sell from Hold at Argus
10/17/22 Barclays
Rocket Companies price target lowered to $5 from $7 at Barclays
09/30/22 Piper Sandler
Rocket Companies price target lowered to $8 from $9 at Piper Sandler
ATUS Altice USA
$4.29 /

+0.19 (+4.64%)

12/01/22 New Street
Altice USA downgraded to Neutral from Buy at New Street
11/09/22 Deutsche Bank
Altice USA price target lowered to $6 from $9 at Deutsche Bank
11/04/22 HSBC
Altice USA upgraded to Buy from Hold at HSBC
11/03/22 Cowen
Altice USA price target lowered to $31 from $39 at Cowen
CUTR Cutera
$51.30 /

+1.3 (+2.60%)

11/22/22 Piper Sandler
Piper would take advantage of any softness in Cutera after competitor approval
10/13/22 Stephens
Cutera resumed with an Overweight at Stephens
10/12/22 Piper Sandler
CMS proposal a positive for Med Tech sector, says Piper Sandler
09/30/22 Piper Sandler
Piper calls Cutera a 'small cap name that investors should own'
SI Silvergate Capital
$26.48 /

+1.25 (+4.95%)

RKT Rocket Companies
$8.40 /

-0.145 (-1.70%)

RIOT Riot Blockchain
$4.97 /

+0.4 (+8.75%)

MSTR MicroStrategy
$206.98 /

+8.55 (+4.31%)

MARA Marathon Digital
$6.91 /

+0.69 (+11.09%)

GRPN Groupon
$8.40 /

-0.33 (-3.78%)

CUTR Cutera
$51.30 /

+1.3 (+2.60%)

ATUS Altice USA
$4.29 /

+0.19 (+4.64%)

  • 07
    Dec
SI Silvergate Capital
$26.48 /

+1.25 (+4.95%)

MSTR MicroStrategy
$206.98 /

+8.55 (+4.31%)

MARA Marathon Digital
$6.91 /

+0.69 (+11.09%)

GRPN Groupon
$8.40 /

-0.33 (-3.78%)

ATUS Altice USA
$4.29 /

+0.19 (+4.64%)

SI Silvergate Capital
$26.48 /

+1.25 (+4.95%)

RKT Rocket Companies
$8.40 /

-0.145 (-1.70%)

RIOT Riot Blockchain
$4.97 /

+0.4 (+8.75%)

MSTR MicroStrategy
$206.98 /

+8.55 (+4.31%)

MARA Marathon Digital
$6.91 /

+0.69 (+11.09%)

GRPN Groupon
$8.40 /

-0.33 (-3.78%)

CUTR Cutera
$51.30 /

+1.3 (+2.60%)

ATUS Altice USA
$4.29 /

+0.19 (+4.64%)

SI Silvergate Capital
$26.48 /

+1.25 (+4.95%)

RKT Rocket Companies
$8.40 /

-0.145 (-1.70%)

RIOT Riot Blockchain
$4.97 /

+0.4 (+8.75%)

MSTR MicroStrategy
$206.98 /

+8.55 (+4.31%)

MARA Marathon Digital
$6.91 /

+0.69 (+11.09%)

GRPN Groupon
$8.40 /

-0.33 (-3.78%)

ATUS Altice USA
$4.29 /

+0.19 (+4.64%)

Periodicals
World Cup is a score for betting stock Entain, Barron's says » 08:48
12/03/22
12/03
08:48
12/03/22
08:48
GMVHF

Entain

$16.66 /

-0.468 (-2.73%)

, MGM

MGM Resorts

$37.07 /

-0.2 (-0.54%)

The twists and turns of…

The twists and turns of the FIFA World Cup, including the U.S. team's nail-biting win against Iran and Saudi Arabia's stunning victory over Argentina, is good news for sports betting giants. British sports betting and gaming group Entain (GMVHF) is one of those set to benefit from the most-watched global sporting event, Callum Keown writes in this week's edition of Barron's. It owns a number of brands, including Ladbrokes, Coral and PartyCasino, and has a joint venture - BetMGM - with MGM Resorts International (MGM). And the growth opportunity in the U.S. - one of the host nations of the next World Cup, in 2026 - can keep the momentum going, the author argues. Reference Link

ShowHide Related Items >><<
MGM MGM Resorts
$37.07 /

-0.2 (-0.54%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

11/30/22 JPMorgan
Entain price target raised to 2,270 GBp from 2,050 GBp at JPMorgan
10/19/22 Barclays
Entain price target lowered to 1,450 GBp from 1,950 GBp at Barclays
10/13/22 Jefferies
Entain price target lowered to 1,900 GBp from 2,025 GBp at Jefferies
10/12/22 Redburn
Redburn launches coverage in online betting, calls Flutter top pick
MGM MGM Resorts
$37.07 /

-0.2 (-0.54%)

11/28/22 Jefferies
Macau concession renewals removes overhang for incumbents, says Jefferies
11/28/22 JPMorgan
DraftKings downgraded to Underweight from Neutral at JPMorgan
11/21/22 Morgan Stanley
MGM Resorts initiated with an Equal Weight at Morgan Stanley
11/03/22 Deutsche Bank
MGM Resorts price target lowered to $49 from $51 at Deutsche Bank
MGM MGM Resorts
$37.07 /

-0.2 (-0.54%)

MGM MGM Resorts
$37.07 /

-0.2 (-0.54%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

MGM MGM Resorts
$37.07 /

-0.2 (-0.54%)

GMVHF Entain
$16.66 /

-0.468 (-2.73%)

MGM MGM Resorts
$37.07 /

-0.2 (-0.54%)

Periodicals
Chinese stock rebound might not last, Barron's says » 08:44
12/03/22
12/03
08:44
12/03/22
08:44
BABA

Alibaba

$89.98 /

+4.06 (+4.73%)

The recent tumult over…

The recent tumult over China's COVID policies may be creating an opportunity in the country's stocks, Reshma Kapadia writes in this week's edition of Barron's. After losing some $1.2 trillion in market value in the past two years, Chinese stocks are rebounding, with Alibaba jumping nearly 10% on Wednesday alone. Risks remain. The next couple of months could be bumpy, as China's transition to a less-restrictive COVID policy comes up against a winter surge in cases and the highly transmissible Omicron variant, the author notes. Reference Link

ShowHide Related Items >><<
BABA Alibaba
$89.98 /

+4.06 (+4.73%)

BABA Alibaba
$89.98 /

+4.06 (+4.73%)

11/18/22 Benchmark
Alibaba price target lowered to $180 from $206 at Benchmark
11/18/22 UBS
Alibaba price target lowered to $135 from $140 at UBS
11/18/22 Truist
Alibaba price target lowered to $120 from $125 at Truist
11/18/22 Baird
Alibaba price target lowered to $120 from $140 at Baird
BABA Alibaba
$89.98 /

+4.06 (+4.73%)

BABA Alibaba
$89.98 /

+4.06 (+4.73%)

BABA Alibaba
$89.98 /

+4.06 (+4.73%)

BABA Alibaba
$89.98 /

+4.06 (+4.73%)

Periodicals
Buy AbbVie, stock still worth owning even as Humira fades, Barron's says » 08:41
12/03/22
12/03
08:41
12/03/22
08:41
ABBV

AbbVie

$163.65 /

+2.03 (+1.26%)

AbbVie's blockbuster…

AbbVie's blockbuster drug Humira faces patent expirations, but there's a lot more to it than the immunosuppressive, Teresa Rivas writes in this week's edition of Barron's. The company has profitable products that have begun to fill the gap left by Humira's decline. Investors who preferred to wait out the transition from Humira may have erred -- AbbVie stock is up by more than 19%, to a recent $162, so far in 2022. Moreover, the stock looks cheap and has a handsome dividend yield. It's worth owning-now, the author argues. Reference Link

ShowHide Related Items >><<
ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

11/17/22 Credit Suisse
AbbVie initiated with an Outperform at Credit Suisse
11/08/22 Societe Generale
AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds
11/08/22 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
10/28/22 Piper Sandler
Piper keeps Overweight rating on AbbVie despite 'rough' Q3 report
ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.